文献速递角膜与眼表疾病

强脉冲光治疗睑板腺疾病:美国眼科学会报告

Intense Pulsed Light for Meibomian Gland Disease: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2020-04-21

美国眼科学会系统综述了强脉冲光(IPL)治疗睑板腺疾病(MGD)的文献,最终纳入12项研究(4项II级证据、8项III级证据)。所有研究均显示IPL治疗后泪膜破裂时间、角膜染色、睑板腺分泌物质量等临床指标改善,副作用少见且自限。尽管部分研究方法学有限,现有证据支持IPL可改善MGD的体征和症状。

要点

  • IPL可改善MGD患者的泪膜破裂时间、角膜染色及睑板腺分泌物质量。
  • IPL副作用少见,包括不适、皮肤红斑、水疱、睫毛脱落和飞蚊症,均自限。
  • 部分研究存在方法学局限和潜在利益冲突,证据等级以II级和III级为主。

核心结论

  • 现有文献表明IPL治疗可改善睑板腺疾病的体征和症状。
  • 尽管部分研究方法学局限和潜在利益冲突引起关注,但证据整体支持IPL的有效性。

研究设计与样本

  • 美国眼科学会报告,通过PubMed和Cochrane Library数据库检索截至2019年5月15日的英文原创研究。
  • 证据等级:4项研究为II级,8项研究为III级。
  • 5项研究存在潜在利益冲突和设计局限,影响结果解读。

主要发现

  • 所有研究均记录到临床有意义的指标改善,包括泪膜破裂时间(TBUT)、角膜染色、睑缘指标、睑脂质量、睑板腺可表达性、眼表疾病指数(OSDI)和标准患者眼干评估(SPEED)问卷评分。
  • 副作用相对少见,包括不适、皮肤红斑、水疱、睫毛脱落和飞蚊症,均自限。

临床怎么用

  • IPL可作为睑板腺疾病和睑板腺相关眼表疾病的一种治疗选择,可改善体征和症状。
  • 治疗前应评估患者是否存在禁忌证,并告知可能的自限性副作用。

局限性

  • 部分研究存在方法学局限和潜在利益冲突,影响证据质量。
  • 纳入研究证据等级以II级和III级为主,缺乏更高级别证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the literature on the efficacy of intense pulsed light (IPL) on the eyelids in the management of meibomian gland disease (MGD) and meibomian gland-related ocular surface disease. METHODS: A literature search was last conducted on May 15, 2019, in the PubMed and Cochrane Library databases for English-language original research that assessed the effect of IPL on MGD in adult patients. Thirty-three articles were identified, and 12 studies were determined to be relevant to the criteria outlined for assessment. The panel methodologist (V.K.A.) assigned a level of evidence rating to each study; 4 studies were rated level II, and 8 studies were rated level III. Five studies had potential conflicts of interest and design limitations that affected interpretation of results. RESULTS: All studies documented improvement in clinically meaningful metrics, including tear breakup time (TBUT), corneal staining and eyelid margin measurements, meibum quality, meibomian gland expressability, ocular surface disease index (OSDI), and standard patient evaluation of eye dryness (SPEED) questionnaire scores. Side effects were relatively uncommon but included discomfort, cutaneous erythema, blistering, eyelash loss, and floaters; these were uniformly self-limited. CONCLUSIONS: Although methodological limitations and potential conflicts of interest in some studies raised concern, the existing body of literature demonstrates improvements in the signs and symptoms of MGD after IPL therapy.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wladis EJ, Aakalu VK, Foster JA, et al. Intense Pulsed Light for Meibomian Gland Disease: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020. PMID: 32327256. doi:10.1016/j.ophtha.2020.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。